Casey C. Case, Ph.D. is SVP Research and Development at 4D Molecular Therapeutics. Dr. Case has 30 years of research experience in the biotechnology industry. He began his career using cell and molecular biology approaches to facilitate the discovery of small molecule drugs, first at OSI Pharmaceuticals and later at Tularik. He then transitioned into protein engineering and gene therapy at Sangamo, developing zinc finger-based transcription factors and gene editors. He then moved to cell therapy at SanBio (modified mesenchymal stromal cells for stroke) and Asterias (embryonic stem cell-derived products for spinal cord injury and immuno-oncology). His most recent work has returned to gene therapy, briefly at Encoded Therapeutics and now at 4D, working to improve the effectiveness of viral gene therapy vectors. Dr. Case received his Ph.D. in Biochemistry from the University of California, Davis and did postdoctoral research in molecular biology with Robert Simons at UCLA.
He has published 52 peer reviewed articles, is an inventor on 34 issued US patents, 33 issued foreign patents and has an additional 117 published patent applications pending. Dr. Case was the author and PI of 14 NIH SBIR grants. He is a member of the advisory boards of the San Francisco State University Biology Department and Professional Science Masters programs. He is on the Scientific Advisory Board and Board of Directors of Arkay Therapeutics.